Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
$2.55M
Mr. David J. Arthur M.B.A.
16.00
Houston, TX
Jan 29, 2015
-0.20
$-8.73
3.17
3.28
0.00%
-0.06
0.22
0.00
3.21
-248.45%
-292.43%
Similar stocks (11)
Corvus Pharmaceuticals, Inc.
CRVS
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Akari Therapeutics, Plc
AKTX
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Pieris Pharmaceuticals, Inc.
PIRS
Vaccinex, Inc.
VCNX
Fresh Tracks Therapeutics, Inc.
FRTX
Artelo Biosciences, Inc.
ARTL
Histogen Inc.
HSTO
ETF Exposure (3)
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
0.03%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (11)
Corvus Pharmaceuticals, Inc.
CRVS
Aileron Therapeutics, Inc.
ALRN
Nutriband Inc.
NTRB
Akari Therapeutics, Plc
AKTX
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Pieris Pharmaceuticals, Inc.
PIRS
Vaccinex, Inc.
VCNX
Fresh Tracks Therapeutics, Inc.
FRTX
Artelo Biosciences, Inc.
ARTL
Histogen Inc.
HSTO
ETF Exposure (3)
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
0.03%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%